Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Bright Minds Biosciences has received a notification from NASDAQ regarding non-compliance with the minimum bid price requirement due to shares closing below $1.00 for thirty consecutive business days. The Company has until July 25, 2023, to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. Despite this notification, trading of the Company's shares will continue uninterrupted. Bright Minds focuses on developing innovative treatments for neuropsychiatric disorders, aiming to create safer and more effective drugs compared to first-generation compounds.
- Trading on NASDAQ and CSE continues uninterrupted.
- Bright Minds focuses on innovative treatments for neuropsychiatric disorders, indicating potential for future growth.
- Received notification from NASDAQ due to share price falling below $1.00 for thirty consecutive days, risking delisting.
VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated January 26, 2023, notifying the Company that due to thirty consecutive business days of closing bid prices for the common shares in the capital of the Company (the “Shares”) being below US
The Company has been provided 180 calendar days, being until July 25, 2023 (the “Compliance Period”), to regain compliance, which may be done by having a closing bid price of at least US
The receipt of the Notification Letter has no immediate effect on the listing of the Company’s Shares, which will continue to trade uninterrupted on each of the Canadian Securities Exchange and NASDAQ under the symbol “DRUG.” To address the issue, the Company will continuously monitor its closing bid prices between now and July 25, 2023, and evaluate its options to regain compliance with NASDAQ Listing Rule 5550(a)(2) before such date. The Company anticipates resolving the deficiency within the compliance period.
About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Investor Contacts:
Lisa Wilson
E: lwilson@insitecony.com
T: 917-543-9932
Ian McDonald
CEO and Director
E: ian@brightmindsbio.com
T: 917-543-9932
This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Forward-looking information in this news release includes statements related to future remedies of the Company’s non-compliance with NASDAQ Listing Rule 5550(2)(a), including its continuous monitoring of the closing price of the Shares or related actions that may be taken to regain compliance. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
FAQ
What did Bright Minds Biosciences announce on January 27, 2023?
What is the current compliance status of Bright Minds Biosciences?
How does the NASDAQ notification impact Bright Minds Biosciences stock?
What are the next steps for Bright Minds Biosciences regarding the NASDAQ compliance?
What is the stock symbol for Bright Minds Biosciences?
